Who
Douglas J. Williamson
Director
Company insider
Files Form 4 as: Director, Vistagen Therapeutics; Executive VP, Research & Dev, ACADIA Pharmaceuticals; Chief Medical Officer, Avadel Pharmaceuticals.
In numbers
- Trades disclosed
- 5
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 14 Feb 2022
- Last trade
- 29 Jul 2026
- Last filed
- 31 Jul 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Jul 2026filed 31 Jul 2026 | VTGN Vistagen Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,826 at $0.00 | filing |
| 29 Jul 2026filed 31 Jul 2026 | VTGN Vistagen Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,826 at $0.00 | filing |
| 10 Feb 2023filed 13 Feb 2023 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —237,296 at $0.00 | filing |
| 10 Feb 2023filed 13 Feb 2023 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —50,655 at $0.00 | filing |
| 14 Feb 2022filed 16 Feb 2022 | Avadel Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —275,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.